Blog

Pharmaceutical consulting firm Accession Healthcare Consulting has received private investments to maintain its current growth rate and support its future growth plans. The medium-sized investment company Alantra advised Accession on the deal.

Founded in 2011 by Elliot and Lindsey Rosen, Accession Healthcare Consulting provides global value and access services to the world’s largest biopharmaceutical companies. Using digital technology that enables customers to enter the market, Accession’s proprietary digital products help pharmaceutical companies develop and launch new pharmaceutical products, transforming the way they interact with their customers.

As the company plans to expand its offering in its tenth year, Accession has received private investment from a group of investors in the healthcare and technology sectors. The investment will support the company’s strong performance and accelerate its ambitious growth plans. This includes providing the means to build the associated strategic resources and capabilities, as well as increasing the number of employees across the company.

Lindsey Rosen, Co-Founder and Director of Accession, commented, “We founded Accession with a real passion to harness the power of market access and ensure patients have access to life changing medicines. It’s a passion that has been the beating heart of everything we do. This investment means we can now work on more pharmaceutical breakthroughs, add value to our customers, and ultimately do our part to achieve the best possible outcomes for patients. ”

Accession was recently named “One to Watch” in the Alantra Pharma Fast 50 2020 – an annual ranking of the UK’s fastest growing private pharmaceutical companies. In relation to this deal, it was the midsize M&A services company Alantra that provided professionals to assist Accession during the investment process. The company was advised by Alantra Pharma Services team members Tom Cowap and Anthony Harrington.

According to Cowap, who writes in Alantras Pharma Fast 50, breakthrough companies like Accession are “focused on creating value – for patients, CROs and large pharmaceutical companies alike,” which drives them to “innovate quickly and pave the way for rapid growth” . Because of this approach, Accession is helping clients who want to bring new therapies to the UK market where the complexity of the NHS poses particular challenges and is now increasingly operating in key European and international markets – making the company an attractive prospect for such an investment .

Commenting on the deal, Elliot Rosen, Co-Founder and General Manager of Accession: “This investment is an important milestone for Accession as we continue to push the boundaries of our work in market access consulting. I am delighted to be working with ambitious and supportive investors to advance the exciting growth plans we have for the company. I’m also really excited about the Accession team. Our dedication to the best talent has always been the foundation of our success, and I look forward to their careers flying for Accession in this new era. “